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Abstract
The development of chemical tool compounds becomes increasingly impor-
tant for chemical biology research projects in many disciplines of life sciences. In 
addition, they form essential parts in both academic and industrial drug discovery 
efforts. The required expertise and technology platforms for the identification and 
optimization of these potent and target-selective small molecules often exceed the 
capabilities of academic groups and smaller companies. Over the years, several 
initiatives were created all over the world which address this issue by either creat-
ing networks or consortia of academic institutes, public-private partnerships with 
industry, or even dedicated new research infrastructures for chemical biology. 
Several of these organizations and their different access models will be described. 
We will focus in particular on the model of EU-OPENSCREEN ERIC, a new 
European Research Infrastructure which was founded in 2018 and consists of more 
than 20 partner institutes from eight countries.
Keywords: academic consortia, chemical tools, drug, pharmacological screening
1. Introduction
In the last decade, the interdisciplinary field of chemical biology has emerged 
from the need to better understand the role of proteins or signaling pathways in 
cellular systems and whole organisms than it was previously feasible with more 
classical genetic tools or methods. Rather than changing the levels of proteins, or 
blocking completely their expression or activity, by deleting or overexpressing their 
respective DNA or RNA sequences, it is now becoming more and more possible to 
precisely modulate their function in a time- and concentration-dependent manner 
using potent, selective and cell-permeable chemical compounds. Although the 
relevance of these so-called chemical tool compounds or probes for solving basic 
mechanistical questions in life sciences is indisputable [1], their role often extends 
into the fields of pharmacology and molecular medicine. In fact, chemical tools 
are playing an important role in the validation of newly identified drug targets in 
pharmaceutical companies, and might even serve as starting points for the develop-
ment of new therapeutics.
Despite recent technological advances in areas such as cryo-electron microscopy 
(Cryo-EM) [2], the major approach for identifying bioactive substances is still the 
systematic testing of compound collections, often comprising many thousands or 
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even millions of individual substances, with target- or pathway-specific biological 
assays which are designed to produce reproducible biological activities with high 
signal-to-noise ratios under experimental conditions which are fast, miniatur-
ized and therefore cost-effective [3]. This approach is technically and logistically 
challenging and, in the past, could only be performed by large pharmaceutical 
companies. In addition to experienced personnel, it requires large facilities with 
often expensive equipment for compound storage, automated liquid handling and 
sensitive detection of biological reactions. In recent years, however, this picture 
started to change. In the wake of the sequencing of the human genome, mostly 
larger academic institutions started to create their own screening and translational 
drug discovery centers because many new potential drug targets were suddenly 
becoming available for which a solid understanding of their physiological roles and 
molecular mechanisms were missing. At the same time, pharmaceutical companies 
faced increased pressures due to high drug development costs, often resulting in 
down-sized research budgets and cost cutting exercises combined with a general 
trend of becoming risk-averse towards innovative drug targets with potential high 
failure rates [4]. As a result, many experienced industrial ‘drug hunters’ found 
employment in academic chemical probe discovery centers, supporting their efforts 
and helping to alleviate some of the initial issues these centers faced [5].
In this chapter we describe some of these new initiatives which were created to 
develop chemical tool compounds outside of the traditional pharmaceutical indus-
try, highlighting their particular strengths, challenges and access models for the 
mostly academic scientific community.
2. Developing chemical probes in academic networks
At the beginning of the 21st century, academic institutions first began to imple-
ment dedicated assay development and screening centers which were soon followed 
by reports on the systematic testing of small molecule compound libraries in the US 
[6]. Comparable efforts in Europe’s research institutes immediately received much 
attention, fostering collaborations between chemistry and biology groups and the 
establishment of academic screening platforms of diverse size. However, single plat-
forms alone could not support comprehensively the needs of academic or industrial 
users due to limited chemical diversity of their compound collections and/or limited 
technical capabilities, and big pharma platforms were at that time not open to 
academic users. Pooling and coordination of public resources and expertise became 
imperative. Therefore, the efforts in the US were replicated with similar initiatives 
in countries such as France (Chimiothèque Nationale), Germany (ChemBioNet), 
Spain (ChemBioBank) and several others. Some years later, long-term coopera-
tions between academic centers from different countries as well as public-private 
partnerships were established. We will describe some of these initiatives in more 
detail and will put particular emphasis on the collaborative model of the youngest 
organization for chemical biology, the EU-OPENSCREEN ERIC.
2.1 The molecular libraries program (MLP) in the US
The large, NIH-funded MLP was created in 2004 with the ambitious goal 
of creating a small molecule probe for every human protein in order to define 
the functions of genes, cells, and whole organisms in health and disease. The 
three components of the initiative were essentially: (a) a network of compre-
hensive and specialized screening centers plus specialized chemistry centers, 
(b) several cheminformatics approaches which included also a newly created 
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public compound database called PubChem with assay metadata, and (c) initia-
tives to generally advance technologies in the fields of chemical diversity, assay 
development and screening [6]. The aim was always to publish the new chemical 
probes and associated data immediately so that compounds could be used by the 
academic scientific community not only for basic research questions, but also 
for mechanistic validation of potentially disease-relevant drug targets and drug 
development.
Individual scientists could apply for funding to the NIH for their assay develop-
ment and screening projects. Successfully, peer-reviewed projects were taken on 
board by one of the MLP centers, and high-throughput screens were conducted 
with a library which, by the end of the program, consisted of 390.000 compounds. 
About 5% of these molecules with often novel scaffolds were delivered by the 
academic synthetic chemistry community. In many cases, further chemical opti-
mization yielded probes against protein targets which were deemed challenging or 
even ‘undruggable’. Overall, during the 10-year period of the program, a total of 375 
chemical tool compounds were developed against a broad range of target classes. 
18 of these compounds were considered sufficiently interesting to serve as starting 
points for the development of therapeutics against a total of eight disease targets 
or target classes, and were licensed to biotech and pharmaceutical companies [7]. 
In light of the investment into the MLP it is debatable whether the ratio of probes 
to drug candidates can be regarded as a success or a disappointment but it certainly 
highlights the difficulties that chemical biologists are facing when they want to keep 
up with the speed of biological discoveries while translating academic findings into 
therapeutics.
2.2 The chemical biology consortium Sweden (CBCS)
Although much smaller than the MLP in the US, this example of a national 
consortium can highlight very well the particular strengths of a focused organiza-
tion with only a few members. CBCS, with two nodes at the Karolinska Institutet 
and Umeå University, was founded as a non-for-profit research infrastructure for 
chemical biology in 2010 [8] by researchers from Biovitrum (former Pharmacia 
and Upjohn) and became an integrated platform of SciLifeLab, an already existing 
national centre for molecular biosciences, in 2013 [9]. The combined platform can 
investigate both chemical and genetic perturbations in biological systems. CBCS 
wants to enable high level basic research with open access publications while at the 
same time linking up academic and industrial groups. Complementary to CBCS, 
SciLifeLab offers a dedicated platform for drug discovery and development, with 
the clear goal of accelerating projects with translational potential. After nearly 
10 years of operation, the consortium has produced more than 130 co-authored 
publications and 11 patent applications while scientific data provided the basis of 
six start-up companies [10].
Users are encouraged to discuss in more detail project proposals with the CBCS 
staff prior to the submission of the official application. A proposal template, user 
agreements and estimated costs of typical screening and chemistry projects are 
available online. Project proposals are evaluated by an independent ‘Project Review 
Committee’ (PRC), which meets biannually. Prioritized projects may be subsidized, 
with the remaining costs covered by the applicant. Implemented projects are periodi-
cally re-evaluated by the Project Review Committee as they progress to pre-defined 
milestones. A project plan for a so-called “large collaborative project” may run over a 
maximum of 2 years for which the user is expected to cover the costs for all reagents 
and consumables, including a compound access fee for plating of library compounds. 
There are also “small collaborative projects” which involve only limited CBCS 
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support for maximal 2 weeks, e.g. a short-term access to a specialized instrument 
such as an imaging plate reader. For these projects, no PRC application is required 
but they are undertaken with a “first come—first served” policy based on available 
resources [10]. In line with the open access data policy of the CBCS, the applicant 
and the CBCS agree upon a clear publication strategy before the implementation 
of the project. The target user group of CBCS are academic researchers at Swedish 
research institutions, who aim to develop chemical probes on a collaborative basis.
It is worth looking in more detail into the services CBCS can offer to their aca-
demic customers. The consortium assists in assay development for both biochemi-
cal and cell-based assays, gives access to the SciLifeLab compound collection and 
provides medicinal and computational chemistry expertise for hit validation and 
optimization. This model is very similar to the service offerings of the much larger 
European research infrastructure EU-OPENSCREEN which is being discussed 
below. In addition, mechanism-of-action studies can be performed with often 
specialized technologies such as cellular thermal shift assays (CETSA) [11]. In fact, 
the development of CETSA is a good example on how an expert consortium such 
as CBCS can impact and further develop disrupting technologies in collaboration 
with local academic groups and commercial partners (here: Pelago Biosciences). 
Starting life as a low throughput assay, CETSA is now amenable to high throughput 
screening [12]. Scientists usually come to the CBCS with the concept for a biological 
assay and first experimental data. They have then the chance to work further on the 
assay in the CBCS laboratories under guidance of their expert scientists, enabling in 
parallel scientific services and the education of users [10].
The CBCS compound collection consists of more than 200.000 compounds with 
high chemical diversity which are routinely quality controlled. While many of these 
compounds were donated by the pharmaceutical company Biovitrum, the library 
was further expanded with sets from commercial vendors and donations by other 
biotech companies. Importantly, the strategy has always been to build a modular 
collection of sub-libraries which can be adapted to the needs of each academic 
screening project, based mainly on assay throughput and cost per data point. For 
instance, in addition to a diverse primary screening set of 35.000 compounds, there 
are also focused libraries for particular target classes such as kinases, G-protein 
coupled receptors, agrochemicals etc., as well as a set of approved drugs [10]. This 
is very different to the concept of EU-OPENSCREEN which offers a high through-
put screening set of 100.000 commercial compounds to their users, with the goal 
to have that set screened in almost all projects so that each compound becomes 
associated with “positive” and “negative” screening data from as many projects as 
possible (see below).
Overall, between 2010 and 2018 more than 400 collaborative projects with 236 
individual users in Sweden were discussed. User interest grew continuously during 
these 8 years, currently leading to approximately one new project discussion per 
week. About 25% of discussions result in large project PRC applications while oth-
ers obtain small project limited support, all documented in, on average, 20 publica-
tions per year [10].
2.3 Public private initiatives: SGC and ELF
In industry, chemical tool compounds play an important role as pharmaceuti-
cal modulators of novel drug targets. Typically, they are being used for testing 
a particular disease hypothesis and for validating the chemical tractability of 
newly discovered candidate proteins or signaling pathways for which otherwise 
comparatively little information is available. Sometimes their properties are even 
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sufficient to act as starting points for drug discovery programs. The development 
of compounds with required potency and, most importantly, selectivity towards 
individual members of a protein class can be a formidable task even for larger 
pharmaceutical or biotech companies. It came therefore as no surprise that in 2009 
several industrial partners decided to collaborate in a pre-competitive manner and 
initiated a public-private partnership (PPP) with leading academic institutes in 
the field of chemical biology. The aim was to develop high-quality chemical tool 
compounds for families of understudied proteins of potential therapeutic value, for 
instance epigenetic and other transcriptional modulators.
The chosen academic partners in that particular PPP were the universities of 
Oxford and Toronto which had already formed the so-called Structural Genomics 
Consortium (SGC) in 2004 with the goal of determining the three-dimensional 
structures of proteins with therapeutic relevance. The SGC advocates open access 
partnerships between industry and academia and is committed to make their 
chemical tool compounds available without any restrictions. In the last 10 years, 
and with financial support by several pharmaceutical companies, more than 50 
chemical probes in the areas of epigenetics and kinase signaling were developed 
[13, 14]. Furthermore, seven pharmaceutical companies made their chemical tool 
compounds from older research programs available to the scientific community, 
including protocols, controls and associated data [15]. Efforts are now underway, 
under the umbrella of the Innovative Medicines Initiative (IMI), to expand the 
initial collection of compounds further by focusing not only on the protein classes 
which were selected in the past but also on the development of new technologies, 
making the identification and profiling of tool compounds generally faster and 
more cost-effective [16].
Another PPP initiative supported by the IMI is the European Lead Factory (ELF) 
[17] which is a consortium of 20 partners, currently among them the universities 
of Oxford and Dundee while several other universities, research organizations and 
companies in the UK, Netherlands and Germany were former partners. The project 
was launched in 2013 and came to an end in 2018, with a follow-up five-year project 
funded in the same year [18]. During its lifetime, the ELF established a selection 
of about 550.000 compounds which are generally not commercially available. 
300.000 of these were donated by seven participating pharmaceutical companies, 
while the rest was synthesized by medicinal chemistry partner companies during 
the last 5 years. Both the compound management facility in the UK and the high 
throughput screening center in the Netherlands were formerly part of pharmaceuti-
cal companies and able to perform screening operations and chemistry services 
such as hit optimization and modeling according to industry standards. The Oxford 
Biotechnology group of the SGC was selected as a key contributor of 3D co-crystal 
structures which are essential for compound optimization. During the lifetime of 
the project, more than 80 drug discovery programs across most therapeutic areas 
were pursued. By March 2018, two partnering deals between the respective project 
owner and one of the pharmaceutical company partners had emerged. Importantly, 
the ELF protects the IP rights of their academic collaborators against the pharma-
ceutical companies, ensuring that the academic researchers can always search for 
external partners in case that no development deal between them and one of the 
ELF industry partners could be fixed. This was one of the main concerns when the 
project started in 2013 [19].
It remains to be seen though if and how academic groups really benefit from 
these ambitious initiatives, especially when own research interests show little 
overlap with the essentially commercial interests of the participating pharmaceuti-
cal companies.
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2.4  The European research infrastructure consortium (ERIC) 
EU-OPENSCREEN
EU-OPENSCREEN [20] is a community-driven, bottom-up initiative in Europe, 
which brings together 21 partner sites, i.e. technology platforms and research 
groups at various universities and research institutions, to form an open-access 
research infrastructure for chemical biology and early drug discovery. Instead of 
building an ivory tower, the aim of EU-OPENSCREEN is to establish and operate 
an infrastructure that facilitates and encourages the engagement with the broader 
scientific community. In the framework of EU-OPENSCREEN, the partner sites 
and external researchers collaboratively develop novel tool compounds (or chemi-
cal ‘probes’) that allow researchers to interrogate and study fundamental cellular 
processes, such as signaling or metabolic pathways.
EU-OPENSCREEN is one of 55 research infrastructures listed on the current 
ESFRI (European Strategy Forum on Research Infrastructures) Roadmap [21] as an 
‘ESFRI Landmark Project’, demonstrating the relevance for the European scientific 
community and the European Research Area (ERA). It is jointly funded by the 
research ministries of eight countries (the Czech Republic, Denmark, Finland, 
Germany, Latvia, Norway, Poland, Spain) and the European Commission. Since 
April 2018, it operates a European, not-for-profit organization (‘European Research 
Infrastructure Consortium’), which is based in Berlin, Germany, and is legally 
independent from any university or research institute. EU-OPENSCREEN, and 
the European Research Infrastructures in general, promote open science and open 
innovation [22].
Many technology platforms at universities and research institutes predominantly 
work with the colleagues at their hosting institution. Larger European initiatives 
often engage with scientists from Western European countries, where these initia-
tives are based. Reaching out to, and encourage the active participation of, scientists 
from regions, which are often underrepresented in chemical biology and early drug 
discovery research, requires a different approach. Through its distributed network 
of partner sites across its member countries, EU-OPENSCREEN aims to have a more 
balanced engagement of local science communities. In each member country, a local 
partner establishes and coordinates a national network—e.g. CZ-OPENSCREEN 
in the Czech Republic, PL-OPENSCREEN in Poland, NOR-OPENSCREEN in 
Norway, Drug Discovery and Chemical Biology Consortium (DDCB) in Finland, 
ChemBioNet in Germany—to raise awareness about the initiative and to efficiently 
encourage scientists at the local level to participate.
2.4.1 The research infrastructure
The EU-OPENSCREEN infrastructure provides open-access to compound 
libraries, assay development and screening facilities, and medicinal chemistry and 
informatics platforms. It provides training and serves as a platform for industry 
engagement.
2.4.1.1 Compound collection
The EU-OPENSCREEN compound collection is a diversity library, which has 
been designed in a collaborative effort of several partner sites. The library is jointly 
used by affiliated EU-OPENSCREEN partner sites for primary screening against 
biological targets solicited from external researchers who developed the appro-
priate assays. During the design of the library, 100,000 commercially available 
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compounds were selected, with an emphasis on chemical stability, absence of reac-
tive compounds, screening-compliant physico-chemical properties, and maximal 
diversity/coverage of chemical space. Furthermore, EU-OPENSCREEN crowd-
sources compounds from external chemists worldwide, in a federated approach 
through its national chemical biology networks. This collection of academic 
compounds will, over time, add increasing uniqueness to the EU-OPENSCREEN 
compound collection. The ambitious goal is to gather up to 40,000 compounds 
over the next years and to realize the vision of a truly European compound collec-
tion. In this context, the EU-OPENSCREEN compound collection will be dynamic 
and expanding. In analogy to the ‘FAIR’ (FAIR stands for findability, accessibility, 
interoperability, and reusability) data principles (described below), structural com-
pound information and quality control data will be available online in an interoper-
able format (interoperability), unique identifier codes for each compound will be 
employed (findability), quality control will ensure the identity and purity of the 
compounds (reproducibility), and their distribution partner sites where they are 
accessible to external scientists and used in screening projects (accessibility). All 
compounds of the collections are carefully characterized and annotated for basic 
physico-chemical (e.g. solubility, light absorbance and fluorescence) and biological 
properties (e.g. cytotoxicity, antibiotic activity) by ‘profiling’ them in a standard 
panel of assays. These bioprofiling data increase the reliability and reproducibility 
of screening results, and identify compounds with properties that could potentially 
perturb specific bioassay read-out technologies (e.g. auto-fluorescence, luciferase 
inhibition, etc.) in order to reduce false-positive results. For chemists who provide 
compounds to be incorporated in the compound collection, these profiling data 
are an important incentive, in addition to the bioactivity data from the screening 
projects.
The jointly used compound collection is stored centrally by the Compound 
Collection Management Facility (CCMF) in Berlin, Germany, and aliquots are 
distributed to the affiliated EU-OPENSCREEN partner sites, which are located 
in the eight EU-OPENSCREEN member countries. The CCMF is responsible for 
the acquisition, selection, maintenance and storage of the central collection and 
quality-controls of the compounds. The CCMF provides the screening and biopro-
filing sites with copies of the compound collection (including, where necessary, 
cherry-picking for confirmatory and counter-screening activities).
2.4.1.2 Database
In many cases, primary screening data—even from publicly funded programs—
are not openly accessible by the scientific community. While private organizations, 
contract research organizations (CROs) and many public-private partnerships 
do not reveal data on a routine basis, EU-OPENSCREEN is committed to maxi-
mizing the re-use and impact of generated bioactivity data for the benefit of the 
wider scientific community. Therefore, EU-OPENSCREEN’s ECBD adheres to the 
FAIR principles [23] and is closely linked to the ChEMBL [24] database, which 
will raise the discoverability and re-use of EU-OPENSCREEN’s data. Via ECBD 
and ChEMBL, database users will be drawn from across the global biological and 
chemical science communities, both from academia and industry. Together with 
other European life sciences-research infrastructures, EU-OPENSCREEN partners 
also contribute towards the optimization of technological implementation, inte-
gration and interoperability of data and tools within the European Open Science 
Cloud (EOSC) and participate in the Horizon 2020-funded ‘EOSC-Life’ project 
(www.eosc-life.eu/). Another initiative, to which the EU-OPENSCREEN partner 
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Fraunhofer IME actively contributes, is the Innovative Medicines Initiative (IMI) 
funded ‘FAIRplus’ project (https://fairplus-project.eu/), which aims to facilitate the 
application of FAIR principles to data from certain IMI projects and datasets from 
pharmaceutical companies.
The ECBD is the central database for the integration of screening data from 
EU-OPENSCREEN projects with advanced search, analysis, and visualization tools. 
There will be three levels of data management and access: First, bioactivity data 
generation of compounds in screening projects, implemented at the individual 
EU-OPENSCREEN screening sites, using assays provided by the external collabora-
tion partners; second, the integration of these screening datasets from partner sites 
into the ECBD; and, third, public dissemination of the data through established 
databases like ChEMBL [24] and PubChem [25, 26]. The ECBD is hosted by Petr 
Bartunek, the coordinator of CZ-OPENSCREEN, and his team at the Institute of 
Molecular Genetics of the ASCR in Prague, Czech Republic, who have developed 
the open data resource Probes & Drugs portal [27] as well as other databases such 
as the Zebrabase [28]. The e-infrastructure CESNET provides cloud-based hosting, 
backup and security.
An important aspect in the context of integrating complex and diverse screening 
data, when dealing with datasets from various affiliated, but legally independent 
sites that jointly use the compound collection, is the implementation of harmonized 
data standards and data curation. The ECBD adheres to well-established ontologies 
and identifiers, for example, the BioAssay Ontology (BAO) [29] for the classifica-
tion and description of assays, which are commonly used by other similar open data 
repositories, such as ChEMBL or PubChem BioAssay. Only officially accredited 
partner sites have permission to upload data into the ECBD and uploaded data will 
be curated both automatically (e.g. file format, column values) as well as manu-
ally (e.g. data inspection) by the ECBD team. In case of ambiguities, the ECBD 
team contacts the data provider to resolve the issue. The ECBD team provides user 
support and help desk functions. Webinars on data deposition, the use of ECBD for 
data searching, visualizations and analysis are planned and dedicated workshops 
will be organized to demonstrate database users all ECBD capabilities and to share 
best practices in the community.
A grace period of up to 3 years between the completion of the primary screen 
and data publication in the EU-OPENSCREEN database is provided, during which 
the bioactivity datasets are not publicly accessible. This grace period allows for 
follow-up studies, publication in peer-review scientific journals and securing of 
intellectual property.
Assay development and screening facilities, and medicinal chemistry 
groups: EU-OPENSCREEN’s affiliated screening partner sites implement the 
EU-OPENSCREEN high-throughput screening (HTS) and High-content screening 
(HCS) projects by using the EU-OPENSCREEN chemical compound collection, 
in collaboration with the external assay developer. They have been operational as 
local groups collaborating with external researchers over the past years, even before 
the EU-OPENSCREEN ERIC has been established. A recent publication showcases 
several successful projects, which have been realized by individual partner sites, as 
an example of the capabilities and expertise within the research infrastructure [20]. 
The chemistry groups have an excellent, proven track record in medicinal chemis-
try and hit-to-lead/tool optimization. As part of the collaborations with external 
researchers, they provide services ranging from the re-synthesis of hit compounds 
and chemical optimization by synthesis of focused libraries containing structurally 
similar analogues, elaboration of structure activity relationships (SAR), and NMR 
and TOF-LC-MS analytics.
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2.4.1.3 Training
The EU-OPENSCREEN partner sites have been operational as local screen-
ing platforms for many years. During this time, they predominantly work with 
their colleagues from the hosting institution and university. By working with the 
same collaborators over a longer time period, both sides could, over the time, 
increasingly gain practical experience and build a knowledge base, for example, 
in developing miniaturized, robust assays which are amendable to screening large 
compound collections. One of the aims of EU-OPENSCREEN is to enable as-yet 
under-served and under-represented user communities, which, by definition, did 
not yet have the opportunity to gain practical experience in these areas. Therefore, 
EU-OPENSCREEN will offer training courses, for example in assay development 
and other aspects of high-throughput screening. Furthermore, staff exchanges at 
established partner sites for scientists from prospective sites in countries that are not 
yet members of EU-OPENSCREEN promote convergence in technical capacities.
2.4.2 Access to the research infrastructure for external researchers
External scientists have open access to a chemical library, assay development and 
screening facilities, medicinal chemistry and informatics platforms. There are three 
main groups of researchers who will benefit from EU-OPENSCREEN:
First, molecular and cell biologists, biochemists, microbiologists, plant biolo-
gists etc. who develop assays which are amendable to screening and are interested 
in developing a chemical ‘tool’ compound for their biological target or pathway 
of interest to answer a biological question or, in the case of disease-relevant tar-
gets, develop new therapeutic approaches to addressing unmet medical needs for 
patients. These scientists benefit from the open access to the screening capabilities 
of EU-OPENSCREEN’s screening partner sites. They are encouraged to contact and 
consult the central office of EU-OPENSCREEN, which acts as a single point of con-
tact for external scientists, prior to submitting a project proposal. Depending on the 
proposal and project requirements, the central office identifies one or more partner 
sites within the network, which offer the appropriate technology and expertise. The 
technical feasibility and scientific novelty will be evaluated. After the project pro-
posal has been accepted, the project is initiated in collaboration with a partner site 
by transferring the assay onto the screening platform. This process often involves 
further optimization and miniaturization into a 384-well or 1536-well plate format, 
with the external scientist, who developed the assay, being actively involved in 
this process at the screening facility. After the screening of the EU-OPENSCREEN 
compound collection at the EU-OPENSCREEN screening site, data analysis and hit 
validation, a list with the validated hits will be available to the assay developer. The 
validated hits will be further optimized either with an EU-OPENSCREEN chem-
istry site or, if the assay provider already has an established collaboration for the 
hit-to-lead/tool optimization, with an external chemist.
Second, organic and medicinal chemists and pharmacologists who seek to 
expose their compounds to a large number of screens, and thereby a wide range of 
biological targets. They provide their compounds to EU-OPENSCREEN, so that 
their compounds are ‘bio-profiled’ and tested as part of the screening collection at 
the EU-OPENSCREEN partner sites. As chemists often have only limited opportu-
nities to systematically annotate their compounds, their incentive to provide their 
compounds to EU-OPENSCREEN is the possibility to identify novel biological 
activities of their compounds. A similar approach to crowd-sourcing academic com-
pounds has been applied over more than a decade within the French Chimiothèque 
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Nationale [30]. Another, more recent opportunity for chemists to screen their 
compounds is the CO-ADD (Community for Open Antimicrobial Drug Discovery) 
[31, 32] initiative, where chemists can test their compounds for antimicrobial activ-
ity against ESKAPE pathogens. These initiatives demonstrate that the prospect of 
receiving bioactivity data is a strong incentive for chemists to donate, and disclose 
the structure and associated bioactivity data of, their compounds.
Third, database users who use EU-OPENSCREEN’s European Chemical Biology 
Database (ECBD) to access the bioactivity datasets generated during the screening 
projects. Importantly, the data will also be accessible through other established open 
data repositories including the ChEMBL database. Assay providers who screen the 
EU-OPENSCREEN compound library benefit from the ECBD for their own projects 
by having access to the public bioactivity data from previous projects, and at the 
same time, they also contribute to worldwide efforts on open science.
2.4.2.1 Access policy and procedure
The democratization of access to state-of-the-art technology platforms, 
resources and expertise is the key objective of all European research infrastruc-
ture. Importantly, as a European open access research infrastructure, a com-
mon access policy and procedure is applied across its network of partner sites. 
EU-OPENSCREEN is accessible to researchers from academia and industry world-
wide. The access to EU-OPENSCREEN by external researchers is in line with the 
‘European Charter for Access to Research Infrastructures—Principles and Guidelines 
for Access and Related Services’ [33] published by the European Commission 
in 2016. The charter’s guidelines describe three access modes, by which access to 
research infrastructures may be provided—these are excellence-driven, market-
driven and wide access. Excellence-driven access is provided to the majority of 
scientists who developed an assay and collaborate with EU-OPENSCREEN to imple-
ment a screening and/or hit optimization project as well as to chemists who provide 
their compounds to be incorporated in the EU-OPENSCREEN compound collection. 
Scientists who use the ECBD will be provided wide access to the bioactivity data.
3. Conclusions
In this book chapter, we described various academic collaboration models which 
aim to accelerate chemical too discovery. These initiatives differ in many aspects, 
for example in structure (e.g. individual academic research groups, public-private 
partnerships, research infrastructures; single-site vs. distributed/multinational), 
operational model (e.g. closed consortia, open-access research infrastructures), 
user communities, funding model (e.g. institutional funding, third-party funding 
over a defined funding period, long-term funding by member countries), access 
and data publication policies. Each of these initiatives complement each other and 
supports academic chemical biology and drug discovery.
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